Previous or concurrent hormonal management of prostate cancer
Contraindication for prescription of Firmagon®
Concurrent treatment with a 5-a-reductase inhibitor
Considered as a candidate for curative therapy
History of severe untreated asthma, anaphylactic reactions or severe urticaria and/or angioedema
QTc interval over 450 msec or risk factors for torsades de pointes or on Class IA and Class III anti arrhythmic medications
Cancer within the last 5 years except prostate cancer and surgically removed basal or squamous cell carcinoma of the skin
Known or suspected hepatic, symptomatic biliary disease (this includes moderate to severe chronic hepatic impairment)
Patients with clinically significant laboratory abnormalities / disorders other than prostate cancer
Patient with Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) infections

NCT02726009_exc_T1
Procedure
hormonal management
NCT02726009_exc_T2
Condition
prostate cancer
NCT02726009_exc_T3
Condition
Contraindication
NCT02726009_exc_T4
Drug
Firmagon
NCT02726009_exc_T5
Drug
5-a-reductase inhibitor
NCT02726009_exc_T6
Procedure
curative therapy
NCT02726009_exc_T7
Condition
asthma
NCT02726009_exc_T8
Qualifier
untreated
NCT02726009_exc_T9
Qualifier
severe
NCT02726009_exc_T10
Condition
anaphylactic reactions
NCT02726009_exc_T11
Condition
urticaria
NCT02726009_exc_T12
Qualifier
severe
NCT02726009_exc_T13
Condition
angioedema
NCT02726009_exc_T14
Measurement
QTc interval
NCT02726009_exc_T15
Value
over 450 msec
NCT02726009_exc_T16
Observation
risk factors for torsades de pointes
NCT02726009_exc_T17
Drug
Class III anti arrhythmic medications
NCT02726009_exc_T18
Drug
 IA an arrhythmic medications
Canc
NCT02726009_exc_T19
Condition
Cancer
NCT02726009_exc_T20
Temporal
last 5 years
NCT02726009_exc_T21
Negation
except
NCT02726009_exc_T22
Condition
prostate cancer
NCT02726009_exc_T23
Condition
squamous cell carcinoma of the skin
NCT02726009_exc_T24
Condition
or sq arcinoma of the skin
Known
NCT02726009_exc_T25
Procedure
surgically
NCT02726009_exc_T26
Scope
basal or squamous cell carcinoma of the skin
NCT02726009_exc_T27
Scope
prostate cancer and surgically removed basal or squamous cell carcinoma of the skin
NCT02726009_exc_T28
Condition
biliary disease
NCT02726009_exc_T29
Condition
, sympt  (thi
NCT02726009_exc_T30
Qualifier
moderate
NCT02726009_exc_T31
Qualifier
severe
NCT02726009_exc_T32
Condition
chronic hepatic impairment
NCT02726009_exc_T33
Scope
moderate to severe
NCT02726009_exc_T35
Condition
 B Virus (HBV),  s
NCT02726009_exc_T36
Condition
 C Virus (HCV) a s
NCT02726009_exc_T37
Condition
HBV
NCT02726009_exc_T38
Condition
HCV
NCT02726009_exc_T39
Condition
unodeficiency Virus (HIV) in s
NCT02726009_exc_T40
Condition
HIV